Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 with Chemotherapy in Resectable NSCLC
NCT05377658Phase 2Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jul 2022
- Primary completion
- Dec 2024
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in non-small cell lung cancer (NSCLC), sponsored by Henan Cancer Hospital. Primary endpoint: Pathological Complete Response Rate. Started Jul 2022; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05377658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05377658.